SCHEMBL10003729

SCHEMBL10003729

CCOC(=O)c1c(OC(C)C)c2nc(-c3ccccc3F)c(CC)cc2n1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.42
▸ LMNA P02545 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ HSD17B10 Q99714 3/20 0.41
▸ HPGD P15428 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ MAPT P10636 4/20 0.41
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ ALOX5 P09917 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ GRM5 P41594 1/20 0.35
▸ TYK2 P29597 2/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10002819 0.90 ALDH1A1 (0.39) ALDH1A1LMNATSHRHSD17B10HPGD
SCHEMBL10003106 0.90 GRIA2 (0.37) ALDH1A1LMNATSHRHSD17B10HPGD
SCHEMBL10003345 0.88 PDE1A (0.39) ALDH1A1HSD17B10MAPTKMT2AALOX5
SCHEMBL10003435 0.87 MLYCD (0.36) ALDH1A1LMNATSHRHSD17B10HPGD
SCHEMBL10003292 0.87 NPC1 (0.44) ALDH1A1LMNATSHRMAPTNPC1
SCHEMBL10003197 0.85 GABRA2 (0.45) ALDH1A1LMNAHSD17B10HPGDNPSR1
SCHEMBL10004406 0.84 TSHR (0.38) ALDH1A1LMNATSHRHSD17B10HPGD
SCHEMBL10003647 0.81 MAPT (0.42) ALDH1A1LMNATSHRHSD17B10HPGD
SCHEMBL10003442 0.81 MAPT (0.40) ALDH1A1MAPTKMT2AALOX5MEN1
SCHEMBL10004041 0.79 MAPT (0.38) ALDH1A1LMNATSHRHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885LMNA 4452/4885TSHR 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback